Ianalumab's Road to Approval for Sjogren's Looks Bumpier
(MedPage Today) -- Findings from a pair of randomized trials in Sjögren's disease with the anti-B cell biologic ianalumab have now been published and it's no longer clear that they're sufficient to support regulatory approvals. The two trials...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.